期刊文献+

人工合成树状串联hTERT表位肽对mDC表型和功能的影响

Effect of Synthesized hTERT Epitopes on the Phenotype and Function of Myeloid Dendritic Cells
原文传递
导出
摘要 目的 通过对树状串联hTERT表位肽(MAP)与无肽刺激组髓样树突状细胞(mDC)的相关检测,研究MAP肽对mDC的表型和功能的影响.方法 人工固相合成四分支的MAP肽,免疫磁珠分选mDC,流式细胞技术检测相关表面分子.ElISA分别检测两组mDC培养基的IL-12p70含量,并作统计学分析.结果 人工合成MAP肽纯度高(95.26 %),免疫磁珠分选mDC纯度为72.59 %,相比于无肽刺激组mDC,MAP肽刺激组成熟(培养第9天)时MHCⅡ类分子为83.90 %、MHCⅠ类分子为91.08 %,CD86:77.03 %,CD83:92.16 %;IL-12p70的含量也大于无肽刺激组,且有统计学差异.结论 人工合成hTERT的MAP肽能足够强的激活mDC,刺激其成熟和功能的表达,可作为mDC抗肿瘤疫苗的刺激肽结构. Objective To explore the role of tandem multiple antigenic peptide (MAP) on myeloid dengritic ceils (mDC) , by comparing the phenotype and function of mDC stimulated by MAP of human telomerase reverse transeriptase (hTERT) epitopes to the control group cells. Methods Four branches of MAP peptides were solid-phase artificially synthesized, mDC cells were isolated through magnetic activated cell sorting (MACS) . The surface molecules of mDC were detected by flow cytometry. The level of IL-12 pT0 was detected by ELISA on both groups respectively and statistically analyzed. Results Synthetic MAP peptide was synthesized with high purity (95.26%) . The rate of mDC with magnetic activated cell sorting was 72. 59%. In MAP peptide stimulated group, MHC Ⅱ molecules reached 83.90%, MHCI 91.08 %, CD86 77. 03%, and CD83 92. 16%, while the control group was 12.92%, 64. 88%, 14. 45% and 26. 32%, when matured in 9-day culture. IL-12p70 secretion was higher than that in the control group, with significant difference. Conclusion The synthesized MAP peptides of hTERT can strongly activate mDC, thus can be used as stimulating peptides in anti-tumor vaccine research.
出处 《医学分子生物学杂志》 CAS CSCD 2011年第2期143-148,共6页 Journal of Medical Molecular Biology
基金 重庆市科委科技攻关项目(No.CSTC2009AC5017)
关键词 人端粒酶逆转录酶 表位肽 髓样树突状细胞 磁珠分选 无血清培养基 human telomerase reverse transcriptase epitopes myeloid dendritic cell magnetic activated cell sorting (MACS) serum free medium
  • 引文网络
  • 相关文献

参考文献22

  • 1BALLESTRERO A,BOY D,MORAN E,et al.Immunotherapy with dendritic cells for cancer[J].Adva Drug Del Rev,2008,60(2):173-178.
  • 2NENCIONI A,GRUNEBACH F,SCHMIDT S M,et al.The use of dendritic cells in cancer immunotherapy[J].Crit Rev Oncol Hematol,2008,65(3):191-199.
  • 3DOMCHEK S M,RECIO A,MICK R,et al.Telomerase-specific T-cell immunity in breast cancer:effect of vaccination on tumor immunosurveillance[J].Cancer Res,2007,67(21):10546-10555.
  • 4WENANDY L,SORENSEN R B,SENGELOV L,et al.The immunogenicity of the hTERT540-548 peptide in cancer[J].Clin Cancer Res,2008,14:4-7.
  • 5LANSDORP P M.Telomeres and disease[J].EMBO J,2009,28:2532-2540.
  • 6CHIANG C L L,BENENCIA F,COUKOS G,et al.Whole tumor antigen vaccines[J].Semin Immunol,2010,22(3):132-143.
  • 7YANNELLI J R,THURMAN G B,DICKERSON S G,et al.An improved method for the generation of human lymphokine activated killer cells[J].J Immun Methods,1987,100(1-2):137-145.
  • 8SCHWARTZENTRUBER D J,HORN S S,DADMARZ R,et al.In vitro predictors of therapeutic response in melanoma patients receiving tumor-infiltrating lymphocytes and interleukin-2[J].J Clin Oncol,1994,12(7):1475-1483.
  • 9RENKVIST N,CASTELLI C,ROBBINS P F,et al.A listing of human tumor antigens recognized by T cells[J].Cancer Immunol Immunother,2001,50(1):3-15.
  • 10ROSENBERG S A.Progress in human tumour immunology and immunotherapy[J].Nature,2001,411(6835):380-384.

相关主题

;
使用帮助 返回顶部